ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

felzartamab

Also written as “Felzartamab”, “MOR202” and “TJ202 and Dexamethasone”.

Its studies are mostly in Glomerulonephritis, IGA · Multiple Myeloma · Glomerulonephritis, Membranous · Myasthenia Gravis · Graves Disease, led by 3 companies.

Drug pageFelzartamab: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Nov 11, 202415 company-led studies, 7 open or runningNext primary completion: Dec 1, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen117 open or runningphase 3since Nov 11, 2024Oct 18, 2019Dec 1, 2026phase 3 · NCT06685757
TJ Biopharmaits history only30 open or runningphase 3since May 14, 2019Jan 15, 2019none ahead
Novartisits history only10 open or runningphase 2since Jul 29, 2011Jul 29, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biogen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2019First study: phase 2 study in Glomerulonephritis, MembranousFirst studyNCT04145440 · 31 enrolled · United States, Australia, Belgium and more
  2. Dec 9, 2019Named felzartamabINNProposed as its International Nonproprietary Name in WHO's List 122 · before, MOR202
  3. Jan 18, 2021Phase 2 study in GlomerulonephritisNCT04733040 · 24 enrolled · Georgia, Germany, Greece and more
  4. Sep 14, 2021Phase 2 study in Kidney DiseasesNCT05065970 · 54 enrolled · United States, Australia, Belgium and more
  5. Sep 26, 2023Phase 1 study in Lupus NephritisNCT06064929 · 14 enrolled · United States, Argentina, Australia and more
  6. Nov 11, 2024Phase 3 study in Antibody-mediated RejectionNCT06685757 · 132 enrolled · United States, Argentina, Australia and more
  7. Apr 17, 2025Phase 3 study in Glomerulonephritis, IGANCT06935357 · 454 planned · United States, Argentina, Australia and more
  8. Oct 17, 2025Phase 2 study in Microvascular InflammationNCT07219043 · 81 planned · United States, Argentina, Australia and more
  9. Feb 26, 2026Phase 3 study in Antibody-mediated RejectionNCT07444489 · 201 planned · United States, Canada
  10. Jul 20, 2026Phase 2 study in Graves DiseaseNCT07722546 · 60 planned · United States, Puerto Rico
  11. Sep 30, 2026Primary completion moved from 2031-05-28 to 2031-12-31Date moved laterphase 3 · +7 months · NCT07444489
  12. Oct 16, 2026Phase 2 study in Glomerulonephritis, IGANCT07889362 · 25 planned
  13. Nov 10, 2026Phase 2 study in Myasthenia GravisNCT07939802 · 75 planned

Ahead

  1. Dec 1, 2026Primary completion: phase 3 study in Antibody-mediated RejectionNCT06685757
  2. May 31, 2027Primary completion: phase 3 study in Glomerulonephritis, IGANCT06935357
  3. Jan 31, 2028Primary completion: phase 2 study in Graves DiseaseNCT07722546
  4. Feb 10, 2028Primary completion: phase 2 study in Microvascular InflammationNCT07219043

TargetBeta

CD38 →read by rule
“A fully human monoclonal antibody directed against the cell surface glycoprotein CD-38 ”NCIt, by rule
“Lymphocyte differentiation antigen CD38 inhibitor”ChEMBL 37, by rule

Other programs on CD38

ProgramCompanyFurthest phaseStudies
daratumumabruleJohnson & Johnsonphase 444
isatuximabruleSanofiphase 323
mezagitamabruleTakedaphase 311
lumrotatugruleKeymed Biosciencesphase 310
Anti-CD38 Monoclonal Antibody SCTC21CruleSinocelltech Groupphase 35
sanritatugruleHangzhou Sumgen Biotechphase 35
CID-103ruleCASI Pharmaceuticalsphase 23
Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001AbbViephase 22
Anti-CD38 Monoclonal AntibodyruleChongqing Genrix Biopharmaceuticalphase 21
Anti-CD38 Antibody-drug Conjugate ABBV-438AbbViephase 11

Studies

All 11 Biogen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07939802Myasthenia Gravis2Not yet recruitingSep 19, 202875
NCT07889362Glomerulonephritis, IGA2Not yet recruitingAug 13, 202825
NCT07722546Graves Disease · United States, Puerto Rico2RecruitingJan 31, 202860
NCT07444489Antibody-mediated Rejection · United States, Canada3By invitationDec 31, 2031201
NCT07219043Microvascular Inflammation · United States, Argentina, Australia and more2RecruitingFeb 10, 202881
NCT06935357Glomerulonephritis, IGA · United States, Argentina, Australia and more3RecruitingMay 31, 2027454
NCT06685757Antibody-mediated Rejection · United States, Argentina, Australia and more3Active, not recruitingDec 1, 2026132
NCT06064929Lupus Nephritis · United States, Argentina, Australia and more1CompletedJun 24, 202614
NCT05065970Kidney Diseases · United States, Australia, Belgium and more2CompletedFeb 6, 202354
NCT04733040Glomerulonephritis · Georgia, Germany, Greece and more2CompletedDec 14, 202324
NCT04145440Glomerulonephritis, Membranous · United States, Australia, Belgium and more2CompletedJan 19, 202231

How it is read

Names in the registry

  • “Felzartamab”, 9 entries
  • “MOR202”, 2 entries
  • “TJ202 and Dexamethasone”, 1 entry
  • “TJ202, Lenalidomide and Dexamethasone”, 1 entry
  • “TJ202 injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.